Kazakhstan’s Chimpharm Posts Ifrs Net Profit Of 331.766 Mln Tenge Against Last Year’s Loss
ALMATY. Nov 10 (Interfax) – Kazakh pharmaceutical company JSC Chimpharm reported a net profit of 331.766 million tenge (341.18 tenge/$1) in January-September 2016 against a loss of 2.701 billion tenge the year before, according to the KASE website.
In the reporting period, the company’s gross profit rose 36.6% to 7.818 billion tenge, revenue up 48% to 15.029 billion tenge, and pre-tax profit amounted to 175.268 million tenge against a pre-tax loss of 3.169 million tenge in January-September 2015.
In January-September 2016, Chimpharm’s assets rose 5.9% to 35.642 billion tenge, short-term liabilities fell 29% to 17.619 billion tenge, long-term liabilities jumped up 9.5 times to 10.106 billion tenge, equity capital grew 4.4 to 7.916 billion tenge, charter capital stood unchanged at 1.683 billion tenge.
JSC Chimpharm is based in the South Kazakhstan region. It currently produces over 200 generic and original medicines. The company’s products are sold both on the domestic market and abroad.
JSC Chimpharm is part of the international pharmaceutical group Polpharma.
(Our editorial staff can be reached at firstname.lastname@example.org)